Aytu Biopharma (AYTU) Free Cash Flow (2010 - 2026)

Aytu Biopharma (AYTU) has reported Free Cash Flow for 17 consecutive years, with -$4.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 35.9% year-over-year to -$4.2 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 127.09% increase from a year earlier, with the FY2025 full-year figure at -$2.2 million, down 26.09% from the prior year.
• Free Cash Flow was -$4.2 million for Q1 2026 at Aytu Biopharma, down from $3.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $9.4 million in Q2 2023 and troughed at -$9.1 million in Q3 2022.
• A 5-year average of -$1.6 million and a median of -$1.1 million in 2024 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow jumped 2247.41% in 2024 and plunged 2468.5% in 2025, its largest moves.
• Over 5 years, Free Cash Flow stood at -$2.5 million in 2022, then jumped by 94.49% to -$135000.0 in 2023, then jumped by 2247.41% to $2.9 million in 2024, then rose by 26.18% to $3.7 million in 2025, then plunged by 214.32% to -$4.2 million in 2026.
• The last three Free Cash Flow figures came in at -$4.2 million (Q1 2026), $3.7 million (Q4 2025), and -$618000.0 (Q3 2025), per Business Quant data.